...
首页> 外文期刊>Radiation oncology >A study of 131iodine-labeling of histamine-indomethacin: its in vivo therapeutic effect and anti-tumor mechanisms in Lewis-bearing lung cancer
【24h】

A study of 131iodine-labeling of histamine-indomethacin: its in vivo therapeutic effect and anti-tumor mechanisms in Lewis-bearing lung cancer

机译:组胺吲哚美辛的 131 碘标记的研究:荷Lewis肺癌的体内治疗作用和抗肿瘤机制

获取原文
           

摘要

Background In our research,we study the effect of 131iodine-labeled histamine-indomethacin (131I-His-IN). We focus on its in vivo therapeutic effect and anti-tumor mechanisms in Lewis-bearing lung cancer. Methods 131I-His-IN was administered by garage to the mice. At different timepoints, we made autoradiography (ARG) slices to observe the distribution of 131I-His-IN in the cellular, and the sliced samples underwent hematoxylin and eosin (HE) staining for observation of tumor necrosis. Before treatment, the groups of mice underwent 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) scans ,and they were then given physiologic saline, iodine 131 (131I), indomethacin (IN), Histamine-indomethacin (His-IN), and 131I-His-IN, respectively, three times daily for seven days. Seven days later, all the mice underwent 18F-FDG PET-CT scans again. We calculated the maximum standard uptake value (SUVmax) of the region of interest (ROI) and tumor inhibition rate at the same time. Results In ARG groups, black silver particle was concentrated in the nucleus and cytoplasm. 131I-His-IN mainly concentrated in tumor tissues. At 8 hours after 131I-His-IN, the radioactivity uptake in tumor tissue was higher than in other organs (F=3.46,P<0.05). For the 18F-FDG PET-CT imaging, the tumor tissus’es SUVmax of the ROI was lower compared to other groups after the treatment with 131I-His-IN. The tumor inhibitory rate (54.8%) in 131I-His-IN group was higher than in other groups, too. In the 131I-His-IN group the vascular endothelial growth factor (VEGF) decreased gradually compared to other groups. The tumor tissue necrotized obviously in 131I-His-IN group. Conclusions Through these animal experiments, we found 131I-His-IN could inhibit the Lewis lung cancer cells. 131I-His-IN focused at the cell nucleus and cytoplasm. It could reduce VEGF and increase tumor inhibitory rate. At the same time, 18F-FDG PET-CT scan could be used for a curative effect and monitoring of disease prognosis.
机译:背景技术在我们的研究中,我们研究了131碘标记的组胺-吲哚美辛(131I-His-IN)的作用。我们专注于其在路易斯小鼠中的体内治疗作用和抗肿瘤机制。方法131I-His-IN通过车库注射给小鼠。在不同的时间点,我们制作了放射自显影(ARG)切片以观察131I-His-IN在细胞中的分布,并对切片的样品进行苏木精和曙红(HE)染色以观察肿瘤坏死。治疗前,对各组小鼠进行18F-氟脱氧葡萄糖(18F-FDG)正电子发射断层扫描计算机断层扫描(PET-CT)扫描,然后给予生理盐水,碘131(131I),消炎痛(IN),组胺-吲哚美辛(His-IN)和131I-His-IN每天7次,每天3次。 7天后,所有小鼠再次进行18F-FDG PET-CT扫描。我们同时计算了感兴趣区域(ROI)的最大标准摄取值(SUVmax)和肿瘤抑制率。结果在ARG组中,黑银颗粒集中在细胞核和细胞质中。 131I-His-IN主要集中在肿瘤组织中。 131I-His-IN后8小时,肿瘤组织中的放射性吸收高于其他器官(F = 3.46,P <0.05)。对于18F-FDG PET-CT成像,在用131I-His-IN治疗后,肿瘤组织的ROI的SUVmax低于其他组。 131I-His-IN组的肿瘤抑制率(54.8%)也高于其他组。与其他组相比,在131I-His-IN组中,血管内皮生长因子(VEGF)逐渐降低。 131I-His-IN组肿瘤组织明显坏死。结论通过这些动物实验,我们发现131I-His-IN可以抑制Lewis肺癌细胞。 131I-His-IN集中于细胞核和细胞质。它可以降低VEGF并增加肿瘤抑制率。同时,18F-FDG PET-CT扫描可用于疗效和监测疾病预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号